MDM2 SNP309 Contributes to Non-Small Cell Lung Cancer Survival in Chinese

被引:20
|
作者
Dong, Jing [2 ]
Ren, Binhui [3 ]
Hu, Zhibin [2 ,4 ]
Chen, Jiaping [2 ]
Hu, Lingmin [2 ]
Dai, Juncheng [2 ]
Jin, Guangfu [2 ]
Xu, Lin [3 ]
Shen, Hongbing [1 ,2 ,4 ]
机构
[1] Nanjing Med Univ, Dept Epidemiol & Biostat, Ctr Canc, Sch Publ Hlth,Key Lab Modern Toxicol, Nanjing 210029, Peoples R China
[2] Nanjing Med Univ, Minist Educ, Key Lab Modern Toxicol, Sch Publ Hlth, Nanjing 210029, Peoples R China
[3] Jiangsu Canc Hosp, Dept Thorac Surg, Nanjing, Peoples R China
[4] Nanjing Med Univ, Dept Clin Epidemiol, Ctr Canc, Nanjing 210029, Peoples R China
基金
中国国家自然科学基金;
关键词
MDM2; polymorphisms; NSCLC; prognosis; SINGLE NUCLEOTIDE POLYMORPHISM; GENETIC POLYMORPHISMS; ONCOPROTEIN MDM2; P53; PATHWAY; RISK; ASSOCIATION; PROMOTER; PROTEIN; SUSCEPTIBILITY; EPIDEMIOLOGY;
D O I
10.1002/mc.20727
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Murine double minute 2 (MDM2) is a negative regulator of the tumor suppressor gene p53. Single nucleotide polymorphisms in MDM2 and p53 can affect patient's response to chemotherapy as well as overall survival of many cancers. This study aimed to assess the associations between polymorphisms in MDM2 and p53 and survival of non-small cell lung cancer (NSCLC) patients in Chinese. We selected and genotyped both potentially functional SNPs and tagging SNPs in MDM2 and p53 using Illumina Golden Gate platform in a cohort of 568 NSCLC patients. Associations between genotypes and NSCLC median survival time (MST) were assessed using the Kaplan-Meier method. Cox proportional hazard models were performed with the adjustment for age, stage, smoking, histology, surgical operation, and chemo-or radiotherapy status. We found that the MDM2 SNP309 (rs2279744) GT/TT genotypes were associated with a significantly worse survival (MST: 23.0 mo for GT/TT vs. 33.0 mo for GG; log-rank P = 0.028). In the multivariate Cox regression analyses, the MDM2 SNP309GT/TT genotypes were associated with a 1.42-fold [HR = 1.42,95% confidence interval (CI), 1.09-1.84] increased risk of death of NSCLC, compared with SNP309GG genotype. MDM2 SNP309 may be used as one of the candidate biomarkers to predict NSCLC survival. (C) 2011 Wiley-Liss, Inc.
引用
收藏
页码:433 / 438
页数:6
相关论文
共 50 条
  • [1] MDM2 SNP309 and SNP285 Act as Negative Prognostic Markers for Non-small Cell Lung Cancer Adenocarcinoma Patients
    Deben, Christophe
    de Beeck, Ken Op
    Van den Bossche, Jolien
    Jacobs, Julie
    Lardon, Filip
    Wouters, An
    Peeters, Marc
    Van Camp, Guy
    Rolfo, Christian
    Deschoolmeester, Vanessa
    Pauwels, Patrick
    JOURNAL OF CANCER, 2017, 8 (12): : 2154 - 2162
  • [2] MDM2 SNP309 and risk of endometrial cancer
    Knappskog, Stian
    Lonning, Per Eystein
    TUMOR BIOLOGY, 2014, 35 (08) : 7285 - 7286
  • [3] MDM2 SNP309 and risk of endometrial cancer
    Knappskog, Stian
    Lonning, Per Eystein
    POLISH JOURNAL OF PATHOLOGY, 2013, 64 (01) : 69 - 70
  • [4] MDM2 SNP309 and risk of cervical cancer
    Knappskog, Stian
    Lonning, Per Eystein
    TUMOR BIOLOGY, 2014, 35 (07) : 6185 - 6186
  • [5] MDM2 SNP309 and SNP354 are not associated with lung cancer risk
    Pine, Sharon R.
    Mechanic, Leah E.
    Bowman, Elise D.
    Welsh, Judith A.
    Chanock, Stephen C.
    Shields, Peter G.
    Harris, Curtis C.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (08) : 1559 - 1561
  • [6] MDM2 SNP309 and risk of endometrial cancer REPLY
    Zajac, Agnieszka
    Stachowiak, Grzegorz
    Pertynski, Tomasz
    Romanowicz, Hanna
    Wilczynski, Jacek
    Smolarz, Beata
    POLISH JOURNAL OF PATHOLOGY, 2013, 64 (01) : 70 - 70
  • [7] MDM2 SNP309 and cancer risk: a combined analysis
    Wilkening, Stefan
    Bermejo, Justo Lorenzo
    Hemminki, Kari
    CARCINOGENESIS, 2007, 28 (11) : 2262 - 2267
  • [8] Mdm2 SNP309 and bladder cancer risk.
    Stoehr, Robert
    Hitzenbichler, Florian
    Hammerschmied, Christine
    Rogenhofer, Michael
    Hartmann, Arndt
    CANCER RESEARCH, 2009, 69
  • [9] MDM2 SNP285 does not antagonize the effect of SNP309 in lung cancer
    Ryan, Brid M.
    Calhoun, Kara M.
    Pine, Sharon R.
    Bowman, Elise D.
    Robles, Ana I.
    Ambs, Stefan
    Harris, Curtis C.
    INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (11) : 2710 - 2716
  • [10] MDM2 SNP309 is associated with endometrial cancer risk
    Terry, Kathryn
    McGrath, Monica
    Lee, I-Min
    Buring, Julie
    De Vivo, Immaculata
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2008, 17 (04) : 983 - 986